Instabilité glycémique et anticorps anti-insuline

[fr] L’instabilité glycémique est courante chez les malades traités par insuline et invalidante en raison des hypoglycémies répétées, soudaines, parfois sévères. Les formulations d’insuline actuelles sont moins immunogènes, mais ont une réactivité croisée avec les anticorps anti-insuline développés contre des insulines antérieures. Une résistance à l’insuline acquise inexplicable ou l’association d’hyperglycémies postprandiales et d’hypoglycémies nocturnes sans proportion avec l’insuline administrée sont suggestives de l’implication des anticorps anti-insuline, mais exceptionnelles en dehors de l’insulinothérapie intra-péritonéale. Vu la prédominance de la pratique inadéquate de l’insulinothérapie, l’hypothèse du rôle des anticorps anti-insuline dans l’instabilité glycémique doit être dûment documentée en hospitalisation avant de pouvoir être retenue.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Renard, E.; CHU de Montpellier

Radermecker, Régis ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Instabilité glycémique et anticorps anti-insuline

Publication date :

October 2008

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson

Volume :

Issue :

Pages :

531-535

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.em-consulte.com/revue/mmm

Available on ORBi :

since 12 October 2009

Statistics

Number of views

235 (9 by ULiège)

Number of downloads

10 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Gill GV, Walford S, Alberti KGMM. Brittle diabetes - present concepts. Diabetologia 1985;28:579-89.
Casparie AF, Elving LD. Severe hypoglycemia in diabetic patients: frequency, causes, prevention. Diabetes Care 1985;8:141-5.
Colombel A, Murat A, Krempf M, et al. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999;16:319-24.
Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23:285-92.
Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996;19:324-7.
Melki V, Renard E, Lassmann-Vague V, et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-82.
Renard E, Schaepelynck-Belicar P; EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 2007;33:158-66.
Badet L, Benhamou PY, Wojtusciszyn A, et al; GRAGIL Group. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation 2007;84,89-96.
Cryer PE. Mechanisms of hypoglycaemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005;54:3592-601.
Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002;19:177-94.
Fineberg SE, Kawabata TT, Finco-Kent D, et al. Immunological responses to exogenous insulin. Endocr Rev 2007;28:625-52.
Greenbaum CJ, Palmer JP. Insulin antibodies and insulin autoantibodies. Diabet Med 1991;8:97-105.
Pinget M, Pradignac A. Retentissement immunologique de l'insulinothérapie. In : Tchobroutsky G, Slama G, Assan R, Freychet P, éditeurs. Traité de diabétologie. Paris:Editions Pradel; 1990. pp.708-11.
Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25:876-82.
Fineberg SE, Huang J, Brunelle R, et al. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003;26:89-96.
Dahl-Jørgensen K, Torjesen P, Hanssen KF, et al. Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes 1987;36:1-5.
Olsen CL, Chan E, Turner DS, et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 1994;17:169-76.
Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-94.
Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007;23:348-55.
Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogues. Am J Clin Dermatol 2007;8:21-8.
Virally ML, Timsit J, Chanson P, et al. Insulin autoimmune syndrome: a rare cause of hypoglycaemia not to be overlooked. Diabetes Metab 1999;25:429-31.
Dozio N, Scavini M, Beretta A, et al. Imaging of the buffering effect of insulin antibodies in the autoimmune hypoglycemic syndrome. J Clin Endocrinol Metab 1998;83:643-8.
Davidson JK, Debra DW. Immunologic insulin resistance. Diabetes 1978;27:307-18.
Shipp JC, Cunningham RW, Russell RO, et al. Insulin resistance: clinical features, natural courses and effects of adrenal steroid treatment. Medicine 1967;44:165-8.
Hanaire-Broutin H, Melki V, Tauber JP. Treatment of acquired immune insulin resistance with i. v. immunoglobulins. Diabetologia 1999;42:1378.
Lassmann-Vague, Belicar P, Alessis C, et al. Insulin kinetics in type 1 diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies. Diabet Med 1996;13:1051-5.
Van Haeften TW, Heiling VJ, Gerich JE. Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin insulin resistance. Implications for intensive insulin regimens. Diabetes 1987;36:305-9.
Scheen A, Henrivaux P, Jandrain B, Lefèbvre PJ. Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabetes Care 1986;9:673-4.
Montaña E, Fernández-Castañer M, Rosel P, et al. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabete Metab (Paris) 1990;16:220-5.
Bousquet-Rouaud R, Chante MA, Orsetti A, et al. Increase in anti-insulin antibody titer during continuous peritoneal insulin infusion. Artif Organs 1990;14(Suppl 3):241-4.
Jeandidier N, Boivin S, Sapin R, et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 1995;38:577-84.
Lassmann-Vague V, Belicar P, Raccah D, et al. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences. Diabetes Care 1995;18:498-503.
Seewi O, Jaeger C, Bretzel RG, Schönau E. Insulin binding to antibodies is a risk factor for inexplicable severe hypoglycaemia in children with type 1 diabetes. Diabetologia 2007;50(Suppl 1):S82 [abstract O185].
Jeandidier N, Boullu S, Busch-Brafin MS, et al. Comparison of antigenicity of Hoechst 21 PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. Diabetes Care 2002;25:84-8.